GlassScriptPhysician profile
M Anis Rahman
NPI 1861416612
$2,367.44
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,152 · 2020: $216.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $323.19 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $310.54 | 2019-2020 | |
| Amgen INC. | $285.83 | 2019-2020 | |
| Pfizer INC. | $238.63 | 2019-2020 | |
| Janssen Biotech, INC. | $203.85 | 2019 | |
| Ucb, INC. | $183.47 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $147.88 | 2019 | |
| Glaxosmithkline, LLC. | $117.01 | 2019 | |
| Celgene Corporation | $115.65 | 2019 | |
| Horizon Therapeutics Plc | $105.19 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $92.86 | 2019-2020 | |
| Gilead Sciences, INC. | $55.63 | 2019-2020 | |
| Genentech USA, INC. | $47.25 | 2019 | |
| Merck Sharp & Dohme LLC | $36.56 | 2019 | |
| Radius Health, INC. | $28.76 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $27.04 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.19 | 2019 | |
| Bioventus LLC | $16.41 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw M Anis Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.